Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons
2018
Aims
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors considerably alter the lipid profile. We sought to examine the rates of ischaemic stroke and neurocognitive deficits in patients treated with and without PCSK9 inhibitors.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
43
References
9
Citations
NaN
KQI